Elicio Therapeutics, Inc. Elicio Therapeutics, Inc.

Elicio Therapeutics, Inc.

ELTX

Rank in Stocks #23275
Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to... Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers. Its development portfolio also encompasses ELI-004, an AMP-modified CpG adjuvant that forms part of ELI-002; ELI-007, a lymph node-targeted AMP-peptide vaccine addressing mutant BRAF-driven cancers; and ELI-008, a multivalent lymph node-targeted AMP-peptide vaccine for cancers expressing mutant TP53. Furthermore, Elicio is advancing ELI-005, a vaccine candidate for preventing COVID-19, and ELI-011 for hematological malignancies. Another program, ELI-012, is an mKRAS TCR T cell AMP-lifier designed for combined use with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company's operations are headquartered in Boston, Massachusetts.
Share Price
$1.59
Last synced: 2026-11-18
Market Cap
$41.80M
Change (1 day)
11.19%
Change (1 year)
-80.10%
Country

Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this

Trade Elicio Therapeutics, Inc. (ELTX)

Category

Healthcare
Operating Margin for Elicio Therapeutics, Inc. (ELTX)
Operating Margin as of November 2026 TTM: 0.00%
According to Elicio Therapeutics, Inc.'s latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2025 the company had an operating margin of 0.00%.
Operating Margin history for Elicio Therapeutics, Inc. from 2012 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
2026 (TTM) 0.00% 0.00%
2025 0.00% 0.00%
2024 0.00% 0.00%
2023 0.00% 0.00%
2022 0.00% -100.00%
2021 -138.84% -92.77%
2020 -1,919.20% -26.05%
2019 -2,595.23% 629.06%
2018 -355.97% 5,793.54%
2013 -6.04% 5.23%
2012 -5.74% 0.00%
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
-195.39% -
US
33.87% -
US
-116.04% -
US
25.57% -
AU
31.23% -
BE
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.

Questions about Elicio Therapeutics, Inc.'s operating margin

What was Elicio Therapeutics, Inc.'s operating margin in 2025?

In 2025, Elicio Therapeutics, Inc.'s operating margin was 0.00%, compared with 0.00% in 2024.

How has Elicio Therapeutics, Inc.'s operating margin changed since 2020?

From 2020 to 2025, Elicio Therapeutics, Inc.'s operating margin was highest in 2025 (0.00%) and lowest in 2020 (-1,919.20%).

How does Elicio Therapeutics, Inc.'s operating margin compare with similar companies?

Elicio Therapeutics, Inc.'s operating margin (0.00%) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 33.87%.